相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Model-Based Quantification of Impact of Genetic Polymorphisms and Co-Medications on Pharmacokinetics of Tamoxifen and Six Metabolites in Breast Cancer
Alicja Puszkiel et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)
Low Z-4OHtam concentrations are associated with adverse clinical outcome among early stage premenopausal breast cancer patients treated with adjuvant tamoxifen
Thomas Helland et al.
MOLECULAR ONCOLOGY (2021)
Generating a Precision Endoxifen Prediction Algorithm to Advance Personalized Tamoxifen Treatment in Patients with Breast Cancer
Thomas Helland et al.
JOURNAL OF PERSONALIZED MEDICINE (2021)
Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group
Kelly E. Caudle et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2020)
Drug monitoring of tamoxifen metabolites predicts vaginal dryness and verifies a low discontinuation rate from the Norwegian Prescription Database
Thomas Helland et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen
A. B. Sanchez-Spitman et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2019)
Patients carrying CYP2C8*3 have shorter systemic paclitaxel exposure
Lauren A. Marcath et al.
PHARMACOGENOMICS (2019)
Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial
Patrick Neven et al.
CLINICAL CANCER RESEARCH (2018)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy
Matthew P. Goetz et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Tamoxifen a pioneering drug: An update on the therapeutic potential of tamoxifen derivatives
Shagufta et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Genetic polymorphisms of 3-untranslated region of SULT1A1 and their impact on tamoxifen metabolism and efficacy
A. B. Sanchez-Spitman et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
The Pharmacogene Variation (PharmVar) Consortium: Incorporation of the Human Cytochrome P450 (CYP) Allele Nomenclature Database
Andrea Gaedigk et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome
A. H. M. de Vries Schultink et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
Effect of OATP1B1 genetic polymorphism on the uptake of tamoxifen and its metabolite, endoxifen
Chun-Mei Ga et al.
ONCOLOGY REPORTS (2017)
Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients
Thomas Helland et al.
BREAST CANCER RESEARCH (2017)
Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring-The TADE Study
Peter Fox et al.
CLINICAL CANCER RESEARCH (2016)
Pharmacogenetics of UGT1A4, UGT2B7 and UGT2B15 and Their Influence on Tamoxifen Disposition in Asian Breast Cancer Patients
Natalia Sutiman et al.
CLINICAL PHARMACOKINETICS (2016)
Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity
Daniel L. Hertz et al.
ONCOLOGIST (2016)
CYP3A4*22 is related to increased plasma levels of 4-hydroxytamoxifen and partially compensates for reduced CYP2D6 activation of tamoxifen
Marina Venzon Antunes et al.
PHARMACOGENOMICS (2015)
Influence of CYP2D6 and CYP3A4 Phenotypes, Drug Interactions, and Vitamin D Status on Tamoxifen Biotransformation
Marina V. Antunes et al.
THERAPEUTIC DRUG MONITORING (2015)
Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer
P. Saladores et al.
PHARMACOGENOMICS JOURNAL (2015)
CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy
Wendy A. Teft et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
PharmGKB summary: tamoxifen pathway, pharmacokinetics
Daniel J. Klein et al.
PHARMACOGENETICS AND GENOMICS (2013)
Toxicity and adverse effects of Tamoxifen and other anti-estrogen drugs
Geniey Yang et al.
PHARMACOLOGY & THERAPEUTICS (2013)
Importance of highly selective LC-MS/MS analysis for the accurate quantification of tamoxifen and its metabolites: focus on endoxifen and 4-hydroxytamoxifen
N. G. L. Jager et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Increasing Tamoxifen Dose in Breast Cancer Patients Based on CYP2D6 Genotypes and Endoxifen Levels: Effect on Active Metabolite Isomers and the Antiestrogenic Activity Score
M. F. Barginear et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma
T. E. Muerdter et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes
L. Madlensky et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors
Philip Lazarus et al.
DRUG METABOLISM REVIEWS (2010)
Impact of OATP transporters on pharmacokinetics
A. Kalliokoski et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
Functional Significance of UDP-Glucuronosyltransferase Variants in the Metabolism of Active Tamoxifen Metabolites
Andrea S. Blevins-Primeau et al.
CANCER RESEARCH (2009)
Pharmacogenomics of Tamoxifen Therapy
Hiltrud Brauch et al.
CLINICAL CHEMISTRY (2009)
Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: The 'personalised' approach?
Hiltrud Brauch et al.
EUROPEAN JOURNAL OF CANCER (2009)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen
MD Johnson et al.
BREAST CANCER RESEARCH AND TREATMENT (2004)
Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: Prominent roles for CYP3A and CYP2D6
Z Desta et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
分享论文
